1. Merck cutting 500 US sales and other commercial positions — Intuitive Surgical crushes Q3 earnings — JNJ stock drops again on new product recall — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Stock price

Discussion in 'Depomed' started by anonymous, May 3, 2017 at 7:07 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    accordong to the proxy materials, Jim owns ~500,000 shares.

    Each share has lost $25 in value

    So Jim has lost $12.5M

    That's rough ...
     
  2. anonymous

    anonymous Guest

    You have other things to think about other than the stock price especially if you are a rep in Az. Let's just say the new DM there enjoys his drink.....a lot.......some might say toooooo much.
    Great hire morons!
     
  3. anonymous

    anonymous Guest

    Posts like this are from ambulance chasing lawyers looking to collect fees from a class action lawsuit. Folks - this isn't Pfizer or some other big cap company. You will make money only when stock price goes up, whether from market improvement or buyout. Don't buy into the bS from the blood sucking lawyers.
     
  4. anonymous

    anonymous Guest

    what you don't know is how crooked JS is...why do you think they stripped him of all of his vested options immediately? there's a lot out there for the lawyers to find....
     
  5. anonymous

    anonymous Guest

    Will Depomed lose these lawsuits?

     
  6. Max999

    Max999 Guest

    Stock price needs to go above Feb 2017 level i.e. $18 in order to win all lawsuits. Not an issue. Not a Problem.
     
  7. Max999

    Max999 Guest

    Management and Starboard should be ashamed of current Stock Price. SB bought at $15. Why do they not buy at these levels? Why is there no Stock Buy Back to give Investors Confidence to invest in this Company? or to negotiate better refinence Terms at higher Stock Prices? Or in case of BO, to demand higher Prices?
     
  8. anonymous

    anonymous Guest

    How the hell should I know?? Find a crystal ball, look into it, and share with the rest of us.

    for those neophytes that are actually thinking about this stupid lawsuit, step back and consider the following - how many years(and it would be years) will this take to settle? How much will I get for my measly 500 shares? 1000 shares? If it takes years, how much of the settlement will be eaten up by YEARS of legal fees? And if we lose - what then?

    We are all pissed off at what many view as a screwed up leadership team. Higgins is here, lets see how he does by the end of 2017. beyond that, its just pissing into the wind.
     
  9. anonymous

    anonymous Guest

    These types of lawsuits are typically settled out of court after several years. On one hand, these price drop law suits arent the most legally sound cases. Investors assume a certain amount of risk. On the other hand, juries usually dont think too highly of corporate America and you put over paid execs on the stand in front of them and then consider the plaintiffs are average joes who lost $$, anything can happen. Couple in the fact that the defendant is a drug company and on top of that an opioid manufacturer under multiple investigations for its contribution to the opioid crisis.....the company can lose this case on the opioid sentiment. This case would not fare well for Depomed in front of a jury.
     
  10. anonymous

    anonymous Guest

    $6 is the new $25 ...

    WE are now running consistently under $6. To break $6 looks good ...
     
  11. anonymous

    anonymous Guest

    Wont happen, Q3 sales are already than Q2. Unless suddenly in the next 5 weeks sales reverse and soar, Q3 ER is going to be a trainwreck. Couple the fact that they cant get a decent rate on refinancing this is going to $3's.
     
  12. anonymous

    anonymous Guest

    Come on, Oct and Dec are the highest months for Rx and Q4 is gonna KICK ASS!!!
     
  13. anonymous

    anonymous Guest

     
  14. anonymous

    anonymous Guest

    Seriously? Then clearly you don't know your own staff. Maybe stop making excuses and start listening to the people that are working for you.
     
  15. anonymous

    anonymous Guest

    So - here's an investment idea for those of us that own stock(options are probably worthless right now).

    The shadow over the opioid market is lasting longer than people expected. Hence, Deposed stock is steadily falling. Home office leadership has left, and we reduced guidance for Wall St. . Lots of things that push us down.

    PAIN WEEK had a lot of talk around litigation, and the focus on overprescribing. Depomed came out of PAIN WEEK looking pretty good, based on conversations I had with ppl that worked the meeting, and Docs that attended. We are still a CII, and have the same warnings as others - but we ARE different. Docs know it. Insurance is getting it as well.

    If you own Deposed stock and are down 50% or more, don't look at the stock price anymore. If you sell now or any time in the next 6-9 months, you will be realizing a big loss. If you already have a bunch of stock, stop your ESPP and pay down bills and other debts. Based on info available today, our stock is only going up on buyout rumors. If we get bought, I guarantee the price will be 100% or more than what we are trading at today.

    The loss is already priced in. Hope that things improve.
     
  16. anonymous

    anonymous Guest

    To the poster above. I appreciate your optimism but it is a little misplaced. The issue of the opioid market is not going anywhere soon. As a matter of fact it will worsen and become more restrictive. Caremark PBM and Anthem Blue Cross just passed further restrictions. Depomed can't live off of Nucynta sales. In a future were abuse deterrence will become a necessity, the drug once again doesn't have the data. It's a CII at the end of the day. As for the stock price it's at a 52 week low. The market cap value of the company is less than its debt, making the company worthless on paper and unattractive for a buy out. Coupled with management issues, and lackluster performance on a portfolio consisting of copy cat drugs that insurers are restricting more and more, the future isn't as bright as you paint it.
     
  17. anonymous

    anonymous Guest


    Optimism? More like realism. There's a reason why Nucynta has over 40% of the market in Europe. Granted, it doesn't have the delivery system technologies of others - but that hasn't done much for those products, right? Times change - and so will this marketplace. Opioids aren't going anywhere - unless you see a fundamental change in insurance covering PT, chiro, etc etc. . I would expect the Gralise and Zipsor business to grow as alternatives to opioids are sought. The expanded CNS team will contribute to better Q4 numbers.
    You make a good point about valuation. The company is making money, so it's not going under. This is definitely a time of poor leadership; perhaps a white knight comes along in 2018. If we get decent $$ from Purdue settlement, that will be bump for stock price too.

    Longs are hurting now - stay the course and hope for the best.
     
  18. anonymous

    anonymous Guest


    Yeah thats all great marketing material, and maybe Arthur uses that in his Q3 earnings call. What Nucynta is doing in Europe has nothing to do with anything unfortunately. Whole diff ball game. Nucynta is no where near as expensive in Europe which is one of the biggest factors here.

    Despite all these great talking points, the fact of the matter is (and this is from our call last week), scripts are declining. Basically we are looking at it like this:

    1. The patient has to find a doctor who will actually prescribe Nucynta
    2. The patients has to actually have insurance that will cover it, few can afford Nucynta out of pocket
    3. If the patient finally gets this far they have to find a pharmacy that will fill it

    So on all 3 fronts you have doctors, insurance companies, and pharmacies all trying to do their part to block a Nucynta sale. Making a sale is a maze, and not everyone is going to get through. Some get #1, but then get suck on #2. #3 is seen as minimal but growing risk with CVS and Walgreens trying to hop on the bandwagon and block peoples meds. Basically at the end of the quarter, the Nucynta script count is total number of people in this country who made it through the maze.

    ...just an interesting way some of us have been looking at it.
     
  19. anonymous

    anonymous Guest

    We should be wondering why bunch of people left the past 30’days.
     
  20. anonymous

    anonymous Guest

    Exactly, and how many are leaving when July payout happens, Sept 30 & August payout happens Oct 31?
    Mass exodus!